- Home
- FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o L-Glutamine, Sodium Pyruvate: 1X Liquid
FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o L-Glutamine, Sodium Pyruvate: 1X Liquid
FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o L-Glutamine, Sodium Pyruvate: 1X Liquid
FluxMPS™ DCP-DMEMLH-QP1X is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid Low Glucose DMEM formulation with 25 mM HEPES, engineered for microphysiological systems (MPS), organ-on-a-chip (OoC), and microfluidic tissue models. The formulation excludes L-glutamine and sodium pyruvate for independent, protocol-specific supplementation, and is dual-buffered with sodium bicarbonate plus HEPES. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.
- Quadruple-stage filtration train: 0.1 µm Prefiltration I → 0.04 µm Final filtration I → 0.1 µm Prefiltration II → 0.04 µm Final filtration II — Polish
- Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85>), tested per manufacturing batch
- Low Glucose (1000 mg/L D-Glucose) + 25 mM HEPES (5958 mg/L) + sodium bicarbonate (3700 mg/L); formulated without L-glutamine and without sodium pyruvate
- Dual-buffer system: HEPES co-buffering supports pH stability alongside bicarbonate across open and closed culture formats
- Manufactured under an ISO 13485:2016 quality management system; final QC at Diagnocine, Totowa, NJ, USA
- Ultrapure Type 1 process water (18.2 MΩ·cm) with trace-metal and organic-carbon (TOC) control
- 32 verified ingredients across three composition categories, released per lot with full raw-material traceability
- Custom pH, glucose, salts, and buffer adjustments available on request — contact support@diagnocine.com
- Formulation[+] Low Glucose, [+] Sodium Bicarbonate, [+] Phenol Red, [+] 25mM HEPES, [+] Calcium, [+] Magnesium | [-] L-Glutamine, [-] Sodium Pyruvate
- AppearanceRed-colored, clear solution (phenol red indicator present)
- pH (USP <791>)7.4
- Osmolality (USP <785>)310–350 mOsm/kg H2O
- Endotoxin (USP <85>)< 0.05 EU/mL
- Sterility (USP <71>)No growth / 14 days
- Filtration0.1 µm ×2 + 0.04 µm ×2
- Total ingredients32
- Storage2–8°C, away from light
- Shelf Life12 months from date of manufacture, unopened
Engineered where standard media fails
Conventional 0.22 µm–filtered media passes fine particulates, protein aggregates, and mycoplasma-scale contaminants that clog microfluidic channels and interfere with sensor readouts. FluxMPS™ reduces these failure modes with a validated quadruple-stage filtration train reaching a 0.04 µm final cut-off, and its dual HEPES/bicarbonate buffer system supports pH stability across sealed and open-top culture formats.
Microchannel-safe purity
0.04 µm final filtration; USP <788> Method 1 (light obscuration) particulate compliance supports safe perfusion across microchannel geometries.
Total metabolic control
Low glucose is provided at a defined level while L-glutamine and sodium pyruvate are left out, letting you titrate carbon and nitrogen sources independently per protocol.
Ultrapure-grade water
Ultrapure Type 1 water (18.2 MΩ·cm) with trace-metal and organic-carbon (TOC) control, reducing extraneous chemical background in the feed water used to compound this medium.
Low background for imaging
Ultra-low particulate count from quadruple-stage filtration supports a cleaner optical field for confocal and biosensor imaging; note this formulation contains phenol red for visual pH indication.
Rich, stable nutrient profile
32 ingredients verified per lot; micro-batch production with full raw-material traceability.
Customization on demand
pH, glucose, salts, HEPES, and nutrients adjustable per your protocol. Contact support@diagnocine.com.
Quadruple-stage filtration system
Four serial filtration stages reach a final 0.04 µm polish. Each 0.04 µm final filter is protected by its own dedicated 0.1 µm prefilter, run in series as two prefilter-plus-final pairs for full redundancy.
-
1
0.1 µm Prefiltration I
Removes large particulate, cell debris, and protein aggregates; protects the first 0.04 µm cartridge.
-
2
0.04 µm Final filtration I
First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a standard 0.22 µm filter, including material in the mycoplasma size range (0.2–0.3 µm).
-
3
0.1 µm Prefiltration II
Second dedicated prefilter, protecting the second 0.04 µm cartridge in the train.
-
4
0.04 µm Final filtration II — Polish
Ultimate polishing filter prior to aseptic fill and finish under ISO Class 5 (Class 100) conditions.
Performance vs. conventional media
© Diagnocine® — DCP-DMEMLH-QP1X
Designed for next-generation cell models
FluxMPS™ DCP-DMEMLH-QP1X supports platforms from single-channel microfluidic chips to multi-organ body-on-a-chip systems. The dual HEPES/bicarbonate buffer system makes it suitable for both closed CO2-incubated formats and open-top microfluidic devices.
Automated Bioreactors & Robotics
An optional 0.01 µm (10 nm) ultra-filtered MPS Grade variant of this formulation is available on request for automated bioreactor perfusion and robotic liquid handlers — see the Grade note above for how this differs from the standard Microfluidics Suitable product.
- Total Particulate Exclusion: 0.01 µm filtration removes nanoparticulate aggregates beyond the standard 0.04 µm train
- Valve & Sensor Protection: Reduces micro-fouling risk on solenoid valves and inline optical sensors
- Extended Perfusion Stability: Supports consistent nutrient delivery over weeks-long culture
Inquiry Required: Contact support@diagnocine.com for the 0.01 µm MPS Grade variant.
Micro Physiological System (MPS) & Chip
Ultra-clean 0.04 µm–filtered media reduces microchannel clogging risk in multi-organ chip architectures.
Warburg Effect & Metabolic Research
Defined Low Glucose formulation without pyruvate supports glycolytic flux studies in cancer and CHO cell lines under controlled carbon-source conditions.
iPSC-Derived Models
Low endotoxin (< 0.05 EU/mL release specification) and mycoplasma-retentive filtration support sensitive iPSC differentiation protocols.
Endothelial & Primary Cells
Low-particulate, endotoxin-controlled media supports HUVEC monolayer integrity for TEER monitoring on chip.
Metabolic Flux Analysis
Defined, glutamine- and pyruvate-free background suits ¹³C isotope tracing and NMR metabolomics workflows. Not compatible with Agilent Seahorse XF assays, which require bicarbonate-free, phenol red-free medium; this formulation contains both.
Microscopy & Optical Sensing
Ultra-low particulate background from quadruple-stage filtration supports confocal and biosensor imaging platforms; this formulation includes phenol red for visual pH monitoring.
Analytical release specifications
Every lot released against the full specification matrix. CoA: support@diagnocine.com.
| Parameter | Specification |
|---|---|
| Formulation | [+] Low Glucose, [+] Sodium Bicarbonate, [+] Phenol Red, [+] 25mM HEPES, [+] Calcium, [+] Magnesium | [-] L-Glutamine, [-] Sodium Pyruvate |
| Appearance | Red-colored, clear solution (phenol red present) |
| pH USP <791> | 7.4 |
| Osmolality USP <785> | 310–350 mOsm/kg H2O |
| Glucose | 1000 mg/L (Low Glucose) |
| HEPES | 25 mM (5958 mg/L), pKa 7.3 at 37°C |
| L-Glutamine | Not added |
| Sodium Pyruvate | Not added |
| Phenol Red | 15.9 mg/L (phenol red sodium salt) |
| Total ingredients | 32 |
| Parameter | Specification |
|---|---|
| Endotoxin USP <85> BET | < 0.05 EU/mL (batch release specification) |
| Sterility USP <71> | No growth / 14 days |
| Mycoplasma | 0.1 µm mycoplasma-retentive filtration (not tested per lot) |
| Particulate ≥10 µm USP <788> Method 1 | NMT 25/mL |
| Particulate ≥25 µm USP <788> Method 1 | NMT 3/mL |
| Water purity | Ultrapure Type 1, 18.2 MΩ·cm |
| Manufacturing std. | ISO 13485:2016 |
| Fill environment | ISO Class 5 (Class 100) |
| Parameter | Specification |
|---|---|
| Storage temperature | 2–8°C, away from light |
| Freeze-thaw | Do not freeze |
| Shelf life | 12 months from date of manufacture, unopened |
| Shipping condition | Cold pack |
| CO2 requirement | Dual-buffered (25 mM HEPES + 44 mM NaHCO3); a sealed incubator requires approximately 10% CO2 to hold pH 7.4 (derived from bicarbonate concentration), while HEPES co-buffering provides reduced CO2 dependence for open-top formats — validate per vessel and cell line |
| Parameter | Specification |
|---|---|
| Raw material grade | Reagent / cell culture grade |
| Traceability | Full lot traceability per ISO 13485 |
| Manufacturing QMS ISO | ISO 13485:2016 certified |
| UNSPSC | 41116155 — Molecular biology and cell culture growth media (UNv260801) |
| Regulatory alignment | 21 CFR Part 820 (QMSR) aligned |
| Production method | Micro-batch, per-lot QC release |
| Intended use | Research Use Only (RUO) |
Full composition (mg/L)
32 ingredients verified per lot with CAS numbers for full raw-material traceability.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium chloride dihydrate | 10035-04-8 | 265.000 |
| Ferric nitrate nonahydrate | 7782-61-8 | 0.100 |
| Magnesium sulfate anhydrous | 7487-88-9 | 97.720 |
| Potassium chloride | 7447-40-7 | 400.000 |
| Sodium bicarbonate | 144-55-8 | 3700.000 |
| Sodium chloride | 7647-14-5 | 6400.000 |
| Sodium dihydrogen phosphate anhydrous | 7558-80-7 | 109.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| Glycine | 56-40-6 | 30.000 |
| L-Arginine hydrochloride | 1119-34-2 | 84.000 |
| L-Cystine dihydrochloride | 30925-07-6 | 62.570 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 42.000 |
| L-Isoleucine | 73-32-5 | 105.000 |
| L-Leucine | 61-90-5 | 105.000 |
| L-Lysine hydrochloride | 657-27-2 | 146.000 |
| L-Methionine | 63-68-3 | 30.000 |
| L-Phenylalanine | 63-91-2 | 66.000 |
| L-Serine | 56-45-1 | 42.000 |
| L-Threonine | 72-19-5 | 95.000 |
| L-Tryptophan | 73-22-3 | 16.000 |
| L-Tyrosine Disodium Salt dihydrate | 69847-15-0 | 109.790 |
| L-Valine | 72-18-4 | 94.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Choline chloride | 67-48-1 | 4.000 |
| D-Ca-Pantothenate | 137-08-6 | 4.000 |
| Folic acid | 59-30-3 | 4.000 |
| Nicotinamide | 98-92-0 | 4.000 |
| Pyridoxal hydrochloride | 65-22-5 | 4.000 |
| Riboflavin | 83-88-5 | 0.400 |
| Thiamine hydrochloride | 67-03-8 | 4.000 |
| i-Inositol | 87-89-8 | 7.200 |
| OTHERS | ||
| D-Glucose | 50-99-7 | 1000.000 |
| Phenol red sodium salt | 34487-61-1 | 15.900 |
| HEPES | 7365-45-9 | 5958.000 |
Manufacturing & compliance
Every FluxMPS™ product is manufactured and released under a multi-layer quality system spanning raw materials, in-process controls, and final-product testing.
ISO 13485:2016 Quality Management
Manufactured under an ISO 13485:2016–certified quality management system. Final QC at the Diagnocine R&D Center, Totowa, NJ, USA.
Ultrapure Type 1 Water
18.2 MΩ·cm resistivity process water with trace-metal and organic-carbon (TOC) control.
ISO Class 5 Fill & Finish
Aseptic fill in validated ISO Class 5 (Class 100) laminar-flow workstations.
Micro-Batch Precision
Small-batch production, full per-lot traceability, Certificate of Analysis for every batch.
Endotoxin — USP <85> BET
LAL assay; assay sensitivity 0.005 EU/mL; batch release specification < 0.05 EU/mL.
Particulate — USP <788> Method 1
Light obscuration: NMT 25/mL (≥10 µm), NMT 3/mL (≥25 µm).
Osmolality — USP <785>
Freezing-point osmometry. Target: 310–350 mOsm/kg H2O.
Documentation & CoA
Full CoA with raw-material traceability available for every batch on request.
- Endotoxin — LAL assay, USP <85> Bacterial Endotoxins Test; assay sensitivity 0.005 EU/mL; release specification < 0.05 EU/mL
- pH, osmolality, conductivity, appearance and clarity
- Sterility
How DCP-DMEMLH-QP1X compares
FluxMPS™ DCP-DMEMLH-QP1X vs. conventional 0.22 µm–filtered DMEM Low Glucose + HEPES formulations.
| Parameter | DCP-DMEMLH-QP1X (FluxMPS™) | Conventional DMEM Low Glucose + HEPES (0.22 µm filtered) | Standard Alt. (0.22 µm filtered) |
|---|---|---|---|
| Grade | Microfluidics Suitable | Not specified | Not specified |
| HEPES-buffered — no L-Glutamine and no Pyruvate for dual metabolic control | check_circle Yes | cancel No | cancel No |
| Final filtration pore size | 0.04 µm | 0.22 µm | 0.22 µm |
| Number of filtration stages | 4 (Quadruple) | 1 | 1 |
| Mycoplasma-retentive filtration | check_circle Yes (0.1 µm stages) | cancel No | cancel No |
| Endotoxin (release specification) | FluxMPS™ — < 0.05 EU/mL | Corning classical liquid media — < 0.25 EU/mL Sigma-Aldrich DMEM complete medium — ≤ 2 EU/mL Gibco classical DMEM — Not specified (recorded per lot) |
|
| USP <788> particulate tested | check_circle Yes (Method 1) | cancel No | cancel No |
| Water quality | Ultrapure Type 1, 18.2 MΩ·cm | Purified water | Purified water |
| Manufacturing QMS | ISO 13485:2016 | ISO 9001 or none | ISO 9001 or none |
| Microfluidic channel compatibility | check_circle Microfluidics Suitable | cancel Higher clogging risk | cancel Higher clogging risk |
| Custom formulation | check_circle Available | cancel Fixed | cancel Fixed |
Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".
Frequently asked questions
Common questions about FluxMPS™ DCP-DMEMLH-QP1X.
Supporting literature
Key peer-reviewed publications supporting Microfluidics Suitable, ultra-filtered media in organ-on-a-chip and microfluidic research.
- Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
- Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
- Ham RG. Clonal growth of mammalian cells in a chemically defined, synthetic medium. Proc Natl Acad Sci USA. 1965;53:288–293. doi:10.1073/pnas.53.2.288
- Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
- Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
- Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
- Reitman ZJ, et al. Metabolic and epigenetic profiling of cancer cells cultured under defined glucose conditions. Cancer Metab. 2019;7:5. doi:10.1186/s40170-019-0198-3
- Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j
